Mostrar el registro sencillo del ítem
dc.contributor.author | Rullán García, Manuel | |
dc.contributor.author | Bulilete, Oana | |
dc.contributor.author | Leiva Rus, Alfonso | |
dc.contributor.author | Soler Mieras, Aina | |
dc.contributor.author | Roca, Antonia | |
dc.contributor.author | Jose Gonzalez-Bals, Maria | |
dc.contributor.author | Lorente, Patricia | |
dc.contributor.author | Llobera Cànaves, Joan | |
dc.contributor.author | PHN Grp | |
dc.date.accessioned | 2024-07-11T09:07:32Z | |
dc.date.available | 2024-07-11T09:07:32Z | |
dc.date.issued | 2017-01-14 | |
dc.identifier.citation | Rullan M, Bulilete O, Leiva A, Soler Mieras A, Roca Jaume A, Gonzalez-Bals MJ, et al. Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. Trials. 2017 Jan 14;18:24. | en |
dc.identifier.issn | 1745-6215 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/9987 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20403 | |
dc.description.abstract | Background: Postherpetic neuralgia (PHN) is a chronic neuropathic pain that results from alterations of the peripheral nervous system in areas affected by the herpes zoster virus. The symptoms include pain, paresthesia, dysesthesia, hyperalgesia, and allodynia. Despite the availability of pharmacological treatments to control these symptoms, no treatments are available to control the underlying pathophysiology responsible for this disabling condition. Methods/design: Patients with herpes zoster who are at least 50 years old and have a pain score of 4 or higher on a visual analogue scale (VAS) will be recruited. The aim is to recruit 134 patients from the practices of general physicians. Participants will be randomized to receive gabapentin to a maximum of 1800 mg/day for 5 weeks or placebo. Both arms will receive 1000-mg caplets of valacyclovir three times daily for 7 days (initiated within 72 h of the onset of symptoms) and analgesics as needed. The primary outcome measure is the percentage of patients with a VAS pain score of 0 at 12 weeks from rash onset. The secondary outcomes measures are changes in quality of life (measured by the SF-12 questionnaire), sleep disturbance (measured by the Medical Outcomes Study Sleep Scale), and percentage of patients with neuropathic pain (measured by the Douleur Neuropathique in 4 Questions). Discussion: Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons. | en |
dc.description.sponsorship | This study was funded by the Ministry of Health, Carlos III Institute (grant PI12/01813). We also received support from the Health Promotion and Preventive Activities-Primary Health Care Network, sustained by the Ministry of Health, Carlos III Institute, Redes Tematicas de Investigacion Cooperativa en Salud (RETIC) award RD12/0005/0011, co-financed by the European Union European Regional Development Fund. The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. | es_ES |
dc.language.iso | eng | en |
dc.publisher | BioMed Central (BMC) | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Postherpetic neuralgia | |
dc.subject | Gabapentin | |
dc.subject | Herpes zoster | |
dc.subject | Prevention | |
dc.subject | Primary health care | |
dc.subject.mesh | Analgesics | * |
dc.subject.mesh | Amines | * |
dc.subject.mesh | Cyclohexanecarboxylic Acids | * |
dc.subject.mesh | Clinical Protocols | * |
dc.subject.mesh | Spain | * |
dc.subject.mesh | Antiviral Agents | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Acyclovir | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Double-Blind Method | * |
dc.subject.mesh | gamma-Aminobutyric Acid | * |
dc.subject.mesh | Pain Measurement | * |
dc.subject.mesh | Herpes Zoster | * |
dc.subject.mesh | Research Design | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Quality of Life | * |
dc.subject.mesh | Time Factors | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Sleep | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Neuralgia, Postherpetic | * |
dc.subject.mesh | Valine | * |
dc.subject.mesh | Surveys and Questionnaires | * |
dc.title | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial | en |
dc.type | research article | en |
dc.rights.license | Attribution 4.0 International | * |
dc.identifier.pubmedID | 28088231 | es_ES |
dc.format.volume | 18 | es_ES |
dc.format.page | 24 | es_ES |
dc.identifier.doi | 10.1186/s13063-016-1729-y | |
dc.relation.publisherversion | https://dx.doi.org/10.1186/s13063-016-1729-y | en |
dc.identifier.journal | Trials | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Sueño | * |
dc.subject.decs | Resultado del Tratamiento | * |
dc.subject.decs | Valina | * |
dc.subject.decs | Factores de Tiempo | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Herpes Zóster | * |
dc.subject.decs | Ácido gamma-Aminobutírico | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Método Doble Ciego | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Calidad de Vida | * |
dc.subject.decs | Proyectos de Investigación | * |
dc.subject.decs | Aciclovir | * |
dc.subject.decs | Protocolos Clínicos | * |
dc.subject.decs | Dimensión del Dolor | * |
dc.subject.decs | Aminas | * |
dc.subject.decs | Encuestas y Cuestionarios | * |
dc.subject.decs | Analgésicos | * |
dc.subject.decs | Antivirales | * |
dc.subject.decs | Ácidos Ciclohexanocarboxílicos | * |
dc.subject.decs | España | * |
dc.subject.decs | Neuralgia Posherpética | * |
dc.identifier.scopus | 2-s2.0-85009387021 | |
dc.identifier.wos | 392029500002 | |
dc.identifier.pui | L614054550 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |